Lexicon Pharmaceuticals, Inc. (LXRX) Financials

LXRX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 250.1 million 75.5 million
March 31, 2026 268.8 million 66.0 million
Dec. 31, 2025 185.0 million 77.4 million
Sept. 30, 2025 205.9 million 85.8 million

LXRX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -23.9 million 6.4 million
March 31, 2026 -14.7 million 3.1 million
Dec. 31, 2025 -17.2 million 2.8 million
Sept. 30, 2025 -23.8 million 3.4 million

LXRX Net Income

No data available :(

LXRX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 190.6 million 51.4 million 7.8 million
March 31, 2026 170.7 million 49.7 million 8.0 million
Dec. 31, 2025 96.2 million 49.4 million 6.6 million
Sept. 30, 2025 116.0 million 56.5 million 8.4 million

LXRX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 437.7 million
March 31, 2026 400.2 million
Dec. 31, 2025 363.4 million
Sept. 30, 2025 363.4 million

LXRX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 17.4 million 9.8 million -
March 31, 2026 - 12.8 million 9.2 million -
Dec. 31, 2025 - 11.2 million 8.8 million -
Sept. 30, 2025 - 18.8 million 7.6 million -

LXRX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 692000 39000
March 31, 2026 21.1 million 108000
Dec. 31, 2025 5.5 million 319000
Sept. 30, 2025 14.2 million 10000

LXRX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

LXRX

Price: $2.34

52 week price:
1.02
2.68

Payout Ratio Range:
-251.52%
-0.96%

Earnings Per Share: -0.15 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 131023

Ebitda: -28.2 million

Market Capitalization: 1.0 billion

Links: